Heterobifunctional small-molecule degraders that induce protein degradation through ligase-mediated ubiquitination have shown considerable promise as a new pharmacological modality. However, we currently lack a detailed understanding of the molecular basis for target recruitment and selectivity, which is critically required to enable rational design of degraders. Here we utilize a comprehensive characterization of the ligand-dependent CRBN-BRD4 interaction to demonstrate that binding between proteins that have not evolved to interact is plastic. Multiple X-ray crystal structures show that plasticity results in several distinct low-energy binding conformations that are selectively bound by ligands. We demonstrate that computational protein-protein docking can reveal the underlying interprotein contacts and inform the design of a BRD4 selective degrader that can discriminate between highly homologous BET bromodomains. Our findings that plastic interprotein contacts confer selectivity for ligand-induced protein dimerization provide a conceptual framework for the development of heterobifunctional ligands.
R ational design of synthetic chemical matter capable of inducing selective protein dimerization is challenging. Significant progress has recently been made toward chemically induced targeted protein degradation using heterobifunctional smallmolecule ligands (often referred to as degraders or PROTACs, for proteolysis-targeting chimeras) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Targeted protein degradation refers to small-molecule-induced ubiquitination and degradation of disease targets, in which a small molecule simultaneously recruits both a ubiquitin E3 ligase and the target protein to be ubiquitinated ( Supplementary Fig. 1a ), therefore representing a functional application of chemically induced protein dimerization 8, 11 . Clinical proof of concept for targeted protein degradation is provided by the recent discovery that the potent anti-cancer drugs thalidomide, lenalidomide and pomalidomide (collectively known as IMiDs, for immunomodulatory drugs) exert their therapeutic effects through induced degradation of key efficacy targets, such as IKZF1, IKZF3 (refs [12] [13] [14] ), ZFP91 (ref. 15 ), or casein kinase 1 alpha (Ck1α ) 16, 17 . IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) E3 ubiquitin ligase [18] [19] [20] , and act by redirecting the activity of the CRL4 CRBN ligase to ubiquitinate these neo-substrates 17 .
PROTACs or heterobifunctional degrader molecules (hereafter referred to as degraders) typically comprise an E3 ligase binding scaffold (hereafter E3-moiety), often an analog of thalidomide, or a ligand to the von Hippel-Lindau tumor suppressor (VHL) protein 21 , attached through a linker to another small molecule (hereafter target-moiety) that binds a target protein of interest ( Fig. 1a and Supplementary Fig. 1b ). Recruitment of this target protein to the E3 ubiquitin ligase facilitates ubiquitination and subsequent degradation of the target protein 22 . This principle has been successfully applied to several targets including the Bromodomain and Extra Terminal (BET) family (BRD2, BRD3, and BRD4), RIPK2, BCR-ABL, FKBP12, BRD9, and ERRα 2,4,6,23-26 and represents a promising new pharmacologic modality now widely explored in chemical biology and drug discovery.
Small-molecule-induced protein degradation by degraders requires ligand-mediated binding of two proteins that have not evolved to interact. Though this is evidently possible, the design of such molecules remains an empirical process in which molecules for new targets frequently fail 9, 27 , likely because of insufficient understanding of the fundamental principles that govern these neo-interactions. Our structural understanding is limited to the recruitment of the second bromodomain of BRD4 (BRD4 BD2 ) to the CUL2-RBX1-ElongB/C-VHL (CRL2 VHL ) ubiquitin ligase by the small molecule MZ1 (1 ) 5 , a degrader that is based on a VHL ligand 21 conjugated to the BRD4 ligand JQ1 (2 ) 28 . Positive cooperativity was observed for VHL-MZ1-BRD2 BD2 , VHL-MZ1-BRD3 BD2 and VHL-MZ1-BRD4 BD2 complex formation, wherein additional contacts between VHL and BRD4 BD2 , as well as back-folding of the linker with additional linker-ligase/substrate contacts, result in superior affinity (linkage cooperativity) compared to the individual affinities for the VHL and BRD4 binding moieties 5 . Whether such tight degrader-mediated complexes are common and whether attractive interprotein forces are required for effective degradation of target proteins that have not evolved to bind to the ligase remains an open question.
Other degraders targeting BRD4 utilize the CRL4 CRBN targeting thalidomide moiety, and it remains to be seen whether these exhibit a similar ligase-substrate interface. In general, degraders have been found to exhibit different efficacy and selectivity profiles depending on the nature of the E3-moiety used, sometimes exhibiting improved selectivity relative to the parental target-moiety 9, 27, 29 . Although positive cooperativity can explain certain cases-such as MZ1-it is unlikely to exist for a broad number of ligase-substrate pairs. We therefore set out to explore general principles that govern these interactions on a molecular level.
Through multiple X-ray crystal structures of degrader-bound CRL4 CRBN -BRD4 complexes, we demonstrate that plastic interprotein contacts result in multiple distinct binding conformations depending on the bound degrader. We establish a model in which effective degradation does not require tight cooperative binding; however, distinct binding conformations are unique to ligase-substrate pairs and define selectivity. We further pioneer a computational approach to protein-protein docking using Rosetta and demonstrate the versatility of this approach through rational design of a degrader that can discriminate between the highly homologous BET bromodomains of BRD2, BRD3, and BRD4, leading to the synthesis of a highly effective and selective BRD4 degrader.
Results
To study the molecular mechanism of substrate recruitment, and because small changes to the degrader can result in dramatically altered cell permeability or solubility, we devised a synthetic system based on the recruitment of isolated BRD4 bromodomains to CRL4 CRBN . Like other members of the BET family, BRD4 contains The chemical structure of dBET23 is depicted with the target-moiety in red, the linker in black and cyan, and the E3-moiety in blue. b, Cartoon representation of DDB1∆ B-CRBN-dBET23-BRD4 BD1 : DDB1 highlighting domains BPA (red), BPC (orange) and DDB1-CTD (gray); CRBN with domains NTD (blue), HBD (cyan) and CTD (green); BRD4 BD1 (magenta). The Zn 2+ -ion is drawn as a gray sphere and dBET23 as stick representation in yellow. The F O − F C map is shown as green mesh for dBET23 contoured at 3.0σ . c, Superposition of DDB1∆ B-CRBN-dBET23-BRD4 BD1 with CRBN bound to lenalidomide (PDB: 4TZ4) and BRD4 BD1 bound to JQ1-(S) (PDF: 3MXF). Surface representations for CRBN and BRD4 BD1 are shown in gray and magenta, respectively. dBET23 is shown in yellow, JQ1 in green, and thalidomide in cyan. d, Side chain interactions between BRD4 BD1 , CRBN and dBET23. Residues of BRD4 BD1 mutated in this study are highlighted in cyan.
two bromodomains: bromodomain 1 (residues 75-147; referred to as BRD4 BD1 ) and BRD4 BD2 (residues 368-440), and sequence conservation between the two is limited ( Supplementary Fig. 1c-e ). These distinct domains bind the JQ1-based target-moiety with equal affinities 28 , and hence establish a model system for understanding how amino acid sequence, and thereby protein surface properties, influence protein dimerization. We further utilize a series of compounds that were synthesized to bind CRBN and the bromodomains of BRD4 (see Supplementary Fig. 1b ; Supplementary Note 1) 6,10 . These molecules comprise the E3-moiety thalidomide to bind to CRL4 CRBN , a flexible linker of variable length and composition, and a target-moiety, JQ1, that binds to BRD4 BD1 and BRD4 BD2 with equal affinities 28 .
Crystal structure of a DDB1∆B-CRBN-dBET23-BRD4 BD1 complex. To determine the structural basis of BRD4 recruitment to CRBN, we reconstituted complexes comprising hsDDB1∆ B (harboring an internal deletion of the flexible BPB propeller 17 ), hsCRBN, and hsBRD4 BD1 bound to different degrader molecules. Initial crystals were obtained for the ~165 kDa DDB1∆ B-CRBN-dBET23-BRD4 BD1 (dBET23 (3 ) comprises an 8-carbon linker attached to thalidomide via an oxyacetamide linkage and to the thiophene group of JQ1) complex, and its structure was determined to 3.5-Å resolution by molecular replacement using a DDB1∆ B-CRBN search model ( Fig. 1b and Supplementary Fig. 1f , PDB: 5FQD; see Methods and Supplementary Table 1 ). The DDB1 β -propeller domains A and C (BPA and BPC) bind CRBN, but do not contribute contacts to BRD4 BD1 . CRBN consists of three domains: the N-terminal domain (NTD), the helical-bundle domain (HBD) and the C-terminal domain (CTD), which harbors the thalidomide binding pocket 20 . The small-molecule degrader dBET23 occupies the canonical binding sites on CRBN and BRD4 BD1 for thalidomide and JQ1, respectively ( Fig. 1c ). BRD4 BD1 interacts with CRBN through contacts with the NTD domain of CRBN and with CRBN residues in direct proximity to the thalidomide binding pocket ( Fig. 1d ). CRBN binds the BRD4 BD1 α C-helix (residues 145-161) and residues in the BRD4 BD1 ZA loop (residues 76-104) 30 . The α C-helix forms hydrophobic interactions with two loops in the CRBN-NTD (residues 101-104 and 147-154). Residues Leu148, Met149, Ala152, and Leu156 in the α C-helix, together with His77 and Phe79 in the ZA loop, form a hydrophobic patch that interacts with Phe102, His103, Phe150, Gly151, Ile152, and Ile154 in the CRBN-NTD. BRD4 BD1 Gln78 forms an electrostatic interaction with Gln100 in the CRBN-NTD ( Fig. 1d ). Consequently, mutations of the BRD4 BD1 residues F79D, A152D, and Q78A all reduce tertiary complex formation, as monitored by measuring the peak height in a TR-FRET dimerization assay ( Fig. 2a and Supplementary  Fig. 2 ; see Methods for details on quantification). We further noticed that Asp145 is buried in a hydrophobic environment, and, accordingly, introducing an D145A mutation strengthens the binding of BRD4 BD1 to CRBN (Fig. 2a ). The interaction between CRBN and BRD4 BD1 consists of a total buried surface area of ~550 Å 2 (ref. 31 ), comparable to that observed for CRBN-Ck1α (~600 Å 2 ) and GSPT1 (~600 Å 2 ) 17, 32 .
In addition to dBET23, we also determined the crystal structures with the related molecules dBET6 (4 ; 3.3-Å resolution) and dBET70 (5 ; 4.4-Å resolution), which both have linkers of similar length, as well as the significantly longer dBET55 (6 ; 4.0-Å resolution and crystallized with BRD4 BD1(D145A) ). The overall structures observed for these complexes are comparable to the structure obtained with dBET23 ( Supplementary Fig. 2a ). As these structures were obtained from crystals with similar space groups and unit cell dimensions, we cannot exclude the possibility that crystal packing may be biased toward the observed binding conformation (see Supplementary  Fig. 2 for discussion).
Interprotein contacts are unique to BRD4 BD1 . The amino acid sequences of BRD4 BD1 and BRD4 BD2 are 49% similar ( Supplementary Fig. 1d ), yet none of the key residues in the α C-helix or the ZA loop involved in contacts with CRBN are identical. We therefore asked whether this would manifest in reduced affinity of BRD4 BD2 for CRBN in the presence of dBET6 or dBET23. While the determination of absolute binding affinities is difficult for a three-body binding problem 33 , a qualitative measure of the relative affinities (or cooperativity of binding) can be indirectly obtained through CRBN-degrader binding assays in the presence or the absence of purified BRD4 BD1 or BRD4 BD2 protein. Using a lenalidomide-Atto565 fluorescent probe, we measured binding of degraders to CRBN by competitive titration (Fig. 2b-e and Supplementary Fig. 3 ). Next, we carried out similar binding experiments in the presence of increasing concentrations of either BRD4 BD1 or BRD4 BD2 to assess the cooperativity of ternary complex formation. We defined an apparent cooperativity factor alpha (α app = IC 50 [binary]/IC 50 [ternary]), with positive cooperativity resulting in α app > 1 and negative cooperativity in BRD4 BD1 and an IC 50 of ~4.1 µ M (α app = 0.2) in the presence of BRD4 BD2 ( Fig. 2c and Supplementary Fig. 3 ), indicative of negative cooperativity for both BRD4 BD1 and BRD4 BD2 . For dBET23 and dBET57 (7 ) , the difference between BRD4 BD1 and BRD4 BD2 is more pronounced, with α app = 0.4 (dBET23) and α app = 0.8 (dBET57) for BRD4 BD1 , and α app < 0.1 for BRD4 BD2 (the binding in the presence of BRD4 BD2 is too weak to quantify), indicating negative cooperativity and a preference for binding to BRD4 BD1 (Fig. 2d ,e and Supplementary Fig. 3 ).
To better understand the drivers of selectivity and to test whether the observed differences in cooperativity would result in differential degradation of isolated BRD4 bromodomains, we developed a system that allowed us to directly quantify cellular degradation of either BRD4 BD1 or BRD4 BD2 . We treated reporter cells stably expressing BRD4 BD1 -EGFP followed by a P2A splice-site separated mCherry with increasing concentrations of degrader molecules (Fig. 3a,b ). This assay format enables quantitative readout of BRD4 BD1 degradation with the GFP/mCherry ratio using flow cytometry (similar reporter cells were used for BRD4 BD2 or a IKZF protein that has internal deletions ∆ 1-82, ∆ 197-239 and ∆ 256-519, hereafter referred to as IKZF∆ ). We found that dBET6 (half-maximal degradation after 5 h of treatment (DC 50/5h ) ~10 nM), dBET23 (DC 50/5h ~50 nM) and dBET70 (DC 50/5h ~5 nM) exhibit the most potent effects on BRD4 BD1 protein levels, followed by dBET1 (8 ; DC 50/5h ~500 nM) and dBET57 (DC 50/5h ~500 nM) ( Fig. 3a and Supplementary Fig. 4 ). For BRD4 BD2 , dBET70 (DC 50/5h ~5 nM) has the most pronounced effects, followed by dBET6 (DC 50/5h ~50 nM), dBET23 (DC 50/5h > 1 µ M) and dBET1 (DC 50/5h ~1 µ M). dBET57, which exhibits significant degradation of BRD4 BD1 , is inactive on BRD4 BD2 ( Fig. 3b and Supplementary Fig. 4 ). The cellular activity is thus largely proportional to the observed cooperativity factors ( Supplementary Fig. 3 ), and dBET57 was found to be remarkably selective for BRD4 BD1 in biochemical and cellular assays ( Fig. 2e and Fig. 3a,b ).
Plastic binding confers selectivity to degraders. When comparing the CRBN-dBET23-BRD4 BD1 structure to the previously determined structures of CRBN-Ck1a 17 and CRBN-GSPT1 (ref. 32 ), we find that these neo-substrates use different surfaces on CRBN to stabilize tertiary complex formation ( Supplementary Fig. 5a ). We also note that molecules with short linkers, such as dBET57, would not be able to dimerize CRBN and BRD4 in the conformation observed in the CRBN-dBET23-BRD4 BD1 structure as a minimum of eight carbons would be required to bridge the E3-moiety with the target-moiety, and dBET57 comprises a two-carbon linker ( Supplementary  Fig. 5c ). We therefore asked whether degrader molecules that are incompatible with the observed binding mode, such as dBET57 or dBET1, would bind in a different overall conformation.
To explore potential differences in binding, we conducted mutational analysis. A set of single amino acid point mutations was introduced in CRBN and BRD4 BD1 to obtain a mutational signature of binding. These CRBN mutations were previously shown to bind thalidomide with comparable affinities except for the IMiDbinding-deficient (IBD) control (CRBN P353G W386A ) 17 . When comparing the mutational signatures of different degraders, we find that whereas dBET6 and dBET23 share similar profiles ( Supplementary Fig. 5 ), consistent with the distinct binding surfaces of dBET6 and dBET23 relative to that of dBET57 ( Fig. 4b,e ). This suggests that different degrader molecules-depending on linker length and linkage position-result in distinct binding conformations of CRBN-BRD4 complex formation.
To obtain insights into the molecular basis of this plastic CRBN-BRD4 BD1 interaction, we set out to crystallize dBET57 ( Fig. 4g-i) , the molecule for which we observe the most pronounced selectivity for BRD4 BD1 over BRD4 BD2 . We obtained crystals for a reconstituted DDB1∆ B-CRBN-dBET57-BRD4 BD1 complex and determined the
BD2 MZ 1 Fig. 3 | Quantitative assessment of cellular degradation for BRD4 BD1 and BRD4 BD2 . a, Quantitative assessment of cellular degradation using a BRD4 BD1 -EGFP reporter assay. Cells stably expressing BRD4 BD1 -EGFP and mCherry were treated with increasing concentrations of dBET1, dBET6, dBET23, dBET55, dBET57, dBET70, MZ1 and lenalidomide (referred to as compounds or CPD) and the EGFP and mCherry signals followed using flow cytometry analysis. b, as in a but using cells that express a BRD4 BD2 -EGFP reporter along with mCherry. Data in a and b are EGFP and mCherry signals quantified using flow cytometry analysis. Data of independent cell culture replicates are presented as the mean ± s.d. (n = 3 for MZ1, dBET6, dBET623, dBET655; n = 4 for dBET1, dBET657, dBET670; n = 6 for lenalidomide). , Surface representation of CRBN highlighting the residues involved in dBET23-mediated BRD4 BD1 binding in orange (residues Y59, L60, Q86, Q100, F102, H103, P104, D149, F150, G151, I152, I154, K156, P352, H353, E377, H378). CRBN interface residues mutated for biochemical assays are indicated. c, TR-FRET. dBET23 titrated to DDB1∆ B-CRBN SPYCATCHER-BODIPY , Terbium-Streptavidin and various BRD4 BD1-biotin wild-type and mutant proteins. The mean peak heights for dose-response curves of three independent replicates are shown as dot-plot. TR-FRET data in this figure are presented as mean ± s.d. d, As in a but titrating dBET57. e, Surface representation of CRBN highlighting the BRD4 BD1 interacting residues for the dBET57-mediated recruitment in orange (residues: Q325, H353, Y355, H357, I371, G372, R373, E377, V388, Q390, C394, A395, S396, H397, T418, S420). CRBN interface residues mutated for biochemical assays are indicated. f, As in c but titrating dBET57. g, Cartoon representation of DDB1∆ B-CRBN-dBET57-BRD4 BD1 : DDB1 highlighting domains BPA (red), BPC (orange) and DDB1-CTD (gray); CRBN with domains NTD (blue), HBD (cyan) and CTD (green); BRD4 BD1 (magenta). The Zn 2+ ion is drawn as a gray sphere. dBET57 was not modeled in this structure, and instead superpositions of lenalidomide (from PDB: 5FQD) and JQ1 (from PDB: 3MXF) are shown in yellow sticks. h, Superposition of CRBN and BRD4 BD1 for the dBET23 and dBET57 containing complexes. Superposition was carried out over the CRBN-CTD (residues 320-400). i, The chemical structures of dBET57 is depicted with the target-moiety in red, the linker in black and cyan, and the E3-moiety in blue. structure to 6.3 Å resolution (see Supplementary Fig. 6 for experimental validation of the structure). Although the limited resolution prevents detailed interpretation of the molecular interactions that govern the CRBN-BRD4 interface, the overall binding mode is clearly resolved ( Fig. 4g and Supplementary Fig. 6 ). In this complex, BRD4 BD1 interacts with the CTD of CRBN instead of the NTD as observed with dBET6 and dBET23 ( Fig. 4g-h) , which results in BRD4 now using an entirely different set of residues for interprotein contexts (compare Fig. 4b,e ). Mutation of the BRD4 residues K91D, K91W, and D145W consequently reduce binding as measured by TR-FRET ( Supplementary Fig. 6d ). In the dBET57-bound structure, we observe that CRBN unfolds and the CRBN-NTD and CRBN-CTD domains no longer interact (Fig. 4g ). This unexpected behavior could be due to the high salt crystallization condition (1.6 M phosphate), or it may be part of intrinsic CRBN plasticity. The binding mode observed with dBET57, however, is fully compatible with a closed CRBN conformation (Fig. 4h) , and dBET57-mediated binding is thus expected to occur with both CRBN conformations (see Supplementary Fig. 6 for additional discussion of CRBN conformation). The unexpected plasticity in degrader-dependent binding of CRBN to the exact same protein, BRD4 BD1 , provides a rationale for how degraders that share the same E3 and target moieties can still exhibit different selectivity profiles. Depending on the linker chemistry and attachment location, different surface residues in the target protein may be involved in complex formation.
Protein docking reveals binding energy landscape. The mutational signatures obtained for different degrader molecules and the structural arrangements for dBET6/23/70 and dBET57 complexes, together with the absence of any co-evolution between CRBN and BRD4, let us hypothesize that BRD4 bromodomains can bind to CRBN in multiple different orientations depending on the ligand. Assessing such potential binding conformations to reduce chemical search space would be highly desirable. In silico protein-protein docking provides an attractive surrogate for in vitro experiments.
We thus asked whether the Rosetta protein docking framework 34 would allow modeling of such possible binding modes. One of the characteristics of Monte Carlo docking algorithms is the stochastic sampling of low-energy conformations, which frequently results in multiple solutions. Although this often complicates the identification of evolved interactions between proteins, sampling of possible conformations provides an advantage in the study of degraderinduced binding modes because it enables exploration of the repertoire of low-energy conformations. We first confirmed that Rosetta can predict ligand-mediated protein-protein interactions by docking Ck1α to the CRBNlenalidomide complex ( Supplementary Fig. 7 ). We next asked whether Rosetta docking would be able to provide models for possible degrader-induced binding modes by docking CRBN and the target BRD4 BD1 in the absence of a degrader molecule. Using the crystal structure of lenalidomide-bound CRBN (PDB: 4TZ4) and JQ1-bound BRD4 BD1 (PDB: 3MXF), we performed a global docking experiment (20,000 models; see Methods) using Rosetta docking ( Supplementary Fig. 7 ). As predicted for the much weaker interaction between CRBN and BRD4 BD1 in the absence of a degrader, multiple low-energy minima were found. Based on the hypothesis that the docking experiment will sample the repertoire of low-energy binding conformations, clustering of the top 200 conformations provides a set of feasible binding modes (see Fig. 5a for three representative clusters). Within those top 200 lowest scoring conformations, we identified a conformation that closely resembles that observed in the dBET23 crystal structure ( Supplementary Fig. 7e,f) , which confirms that some of the clusters represent conformations present in solution. Although it remains to be shown whether docking can accurately predict binding modes, the overall conformational landscape provides a rationale for the design of required minimal linker lengths and suggests suitable linkage positions (Fig. 5 ). To test whether the docking information can be used to inform the design of degraders, we calculated the pairwise shortest distances between the selected solvent-exposed atoms of JQ1 and lenalidomide for all top 200 poses and found a distance of 3-4 Å, corresponding to a linker of 2-3 atoms that was sufficient to bridge the two moieties (Fig. 5b,c) . In theory, the shortest possible linker for a ligase-target pair should provide the most selective compound, because it will restrict the degrees of freedom for BRD4 BD1 binding to CRBN. This short linker length conformation was found to represent Cluster 19 (Fig. 5c ). To test the prediction that such a short linker would result in a selective molecule, we next synthesized the according molecule (ZXH-2-147 (9 )). Cellular degradation assays show that ZXH-2-147 is active on BRD4 BD1 , in accordance with the docking results ( Supplementary Fig. 8a) , albeit with reduced activity compared to dBET6. To improve activity, we optimized the linker length by + 2, + 1, and − 1 carbons and arrived at ZXH-3-26 (10 ) (Fig. 6a ). Cellular degradation assays show that ZXH-3-26 exhibits a DC 50/5h ~5 nM, which is comparable to the best pan-BRD degrader dBET6 (Fig. 6b ). To test whether these molecules exhibit isoform selectivity, we expanded our cellular reporter system to include the individual bromodomains of BRD2 and BRD3 and tested cellular degradation along with BRD4. We found that ZXH-3-26 shows activity exclusively on the first bromodomain of BRD4 and spares degradation of BRD2 or BRD3 at concentrations > 10 µ M (Fig. 6b) , whereas dBET6 and MZ1 controls show activity on most bromodomains (Fig. 6c,d ).
Next, we assessed bromodomain degradation for dBET57 to test whether any short linker would result in selectivity for BRD4 BD1 . In assessment of cellular degradation using an EGFP/mCherry reporter assay. Cells stably expressing BRD4 BD1 -EGFP (or constructs harboring BRD2 BD1 , BRD2 BD2 , BRD3 BD1 , BRD3 BD2 , or BRD4 BD2 ) and mCherry were treated with increasing concentrations of ZXH-3-26, and the EGFP and mCherry signals were analyzed using flow cytometry. c-e, As in b but for dBET6 (c), MZ1 (d) and dBET57 (e). Data in b-e are representative of at least three independent experiments. f, Cellular degradation of endogenous BRD4. HEK293T cells were treated with increasing concentrations of ZXH-3-26 or dBET6 for 5 h, and protein levels were assessed by western blot. g, As in f but assessing the degradation of BRD2 and BRD3 by western blot. Experiments in f and g are representative of two independent experiments. Full scans for all western blots are provided in Supplementary Fig. 10 . h, Scatter plot depicting the fold changes in relative abundance comparing treatment with 0.1 µ M ZXH-3-26 to that with DMSO control for 4 h in MM.1 s cells determined using quantitative proteomics. Negative log 10 false discovery rate (FDR) adjusted P values are shown on the x axis and log2 fold changes on the y axis. BRD4 is significantly downregulated with a log2 fold change of − 1.99, and a FDR adjusted P value of 0.0018. Data shown are of three cell culture replicates measured in a single 10-plex TMT experiment (showing 6,311 proteins quantified by > 3 unique peptides). P values were derived from a moderated t-statistic using the limma package (twos ided) and corrected for multiple hypothesis testing using a Benjamini-Hochberg approach (see Methods for details) 40 .
contrast to ZXH-3-26, dBET57 is nearly equipotent on BRD3 BD1 and BRD4 BD1 (Fig. 6e) . To test whether the selective ZXH-3-26 retains activity on endogenous full-length BRD4, we treated HEK293T cells with increasing concentrations of ZXH-3-26. Immunoblot analysis confirms that ZXH-3-26 degrades endogenous BRD4 with comparable efficacy to the best pan-BET degrader dBET6 (Fig. 6f ), but is inactive on BRD2 and BRD3 (Fig. 6g ). Our docking results suggest that ZXH-3-26 would engage CRBN in a conformation distinct from what was observed with dBET6, dBET23 or dBET57 ( Supplementary Fig. 8d-h) , which is confirmed by distinct mutational profiles ( Supplementary Fig. 5 ). Interestingly, mutation of Gln84 to Arg (as in BRD2, or Lys as in BRD3; see Supplementary  Fig. 8d-j) decreases complex formation with CRBN mediated by ZXH-3-26, consistent with the observed specificity for BRD2 and BRD3. Finally, whole proteome mass spectrometry confirmed that upon treatment with ZXH-3-26, BRD4 is the only significantly downregulated target ( Fig. 6h and Supplementary Dataset 1) compared to dBET23 or dBET70 ( Supplementary Fig. 9 and Supplementary Dataset 1) . ZXH-3-26 thus demonstrates that binding to a distinct conformation can yield a highly selective degrader molecule and that selectivity can be achieved across highly homologous domains such as the bromodomains of BET proteins.
Discussion
Here, we use an integrated approach combining structural, biochemical, and cellular data to establish the molecular basis of degrader-mediated neo-substrate recruitment to the CRL4 CRBN E3 ubiquitin ligase. We show that interprotein contacts, while contributing relatively little binding affinity to the interaction, can be drivers of selectivity, and that highly effective degraders (for example, the low-nanomolar cellular activity of dBET6 or dBET70) can be achieved in the absence of tight binding or positive cooperativity. Through multiple X-ray crystal structures, together with comprehensive biochemical, cellular, and computational characterization, we show that binding between the ligase and the substrate is plastic and can adapt distinct conformations depending on linker length and position. We show that exploiting such 'local' energy/entropy minima underlies selectivity, as seen for dBET57. We demonstrate that in silico protein docking can be used to reveal low-energy binding modes and can guide development of the first heterobifunctional degraders that can discriminate between the highly homologous BET bromodomains, such as ZXH-2-147 and ZXH-3-26. Finally, we demonstrate that biochemical properties translate to cellular activity with respect to BRD4 on-target and IKZF1 off-target degradation, and that IKZF1 degradation can be tuned by IMiD linker composition ( Supplementary Fig. 9 ).
Our data demonstrates that the same two proteins can bind in different overall conformations, resulting in distinct surface patches on the ligase and the target to interact. Degraders therefore appear to exploit natural and widely occurring nonspecific interactions by increasing the local concentration of the two protein binding partners. Nonspecific interactions are widespread and are thought to occur between any two proteins with affinities > 10 mM 35 . However, these interaction surfaces are not random, as they require a certain degree of surface complementarity to avoid unfavorable contacts such as opposing charged surfaces. The constraints of relatively short linkers result in only few accessible interprotein contact conformations. In theory, rationally designed linkers that are restricted to a specific binding mode unique to a ligase-substrate pair should be sufficient to drive selectivity because such a restricted conformation is unlikely to occur even in a close ortholog. We show that this can be achieved in practice with the tool compound ZXH-3-26.
The absence of positive cooperativity and the existence of multiple distinct binding conformations carries further important implications. The lack of a requirement for high-affinity ligase-substrate interactions implies that a wide variety of E3 ligases can be explored to achieve desirable properties such as tissue specificity. With dBET57 and ZXH-3-26 we demonstrate that effective degraders can be designed to harbor relatively short linkers, which results in favorable and more 'drug-like' properties overall ( Supplementary  Fig. 1 ). We show that such short linker compounds exhibit high selectivity because the number of accessible binding conformations is reduced. Selectivity can also be further explored using different E3-moeities, as seen for CRBN-and VHL-targeting degraders (Fig. 3a) . We demonstrate that computational modeling can provide an elegant surrogate, as it depends only on a known structure for the individual components (ligase and target) and has the potential to enable initial predictions of possible linker length and trajectory to guide medicinal chemistry.
ZXH-3-26, to our knowledge, represents the first small molecule to allow pharmacologic targeting of BRD4 without significant inhibition or degradation of BRD2 and BRD3. The notion that pharmacological selectivity can be achieved through induced protein-protein interactions distal from the immediate binding site of the small molecule affords new opportunities for the development of target-specific degrader molecules. The ability to selectively degrade BRD4 has potential implications for future drug development efforts, as efficacy of BRD4 downregulation has been established for a variety of malignancies 36, 37 . Although pan BET inhibitors show toxicity, as observed in preclinical and clinical studies 38 , it is conceivable that selective degradation of BRD4 will retain efficacy while significantly reducing pan-BET-dependent toxicity, for example, in NUT midline carcinomas, which uniquely depend on the BRD4-NUT fusion protein. Such selective targeting of an oncogenic fusion protein has been shown to be an effective treatment strategy in the case of BCR-ABL and Gleevec 39 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0055-y.
Constructs and protein purification. Wild-type and mutant versions of human DDB1, human CRBN, and human IKZF1Δ were cloned in pAC-derived vectors 41 , and recombinant proteins were expressed as N-terminal His 6 (DDB1∆ B, CRBN), StrepII-Avi (IKZF1Δ ) or His 6 -3C-Spy 42 (CRBN) fusions in Trichoplusia ni High-Five insect cells using the baculovirus expression system (Invitrogen). Wild-type and mutant BRD4 BD1 and BRD4 BD2 subcloned into E. coli pET100/D-TOPO vector with N-terminal His 6 -Avi fusions were obtained from Invitrogen, and BRD4 BD1/2 were subcloned into N-terminal His 6 -MBP-TEV-Spy pETDuet vector and all expressed in BL21-DE3 or BL21-DE3 Rosetta cells using standard protocols. The His 6-TEV-BRD4 BD1 construct used for selenomethionine derivative was a gift from S. Dhe-Paganon (originally Addgene: 38942) and was expressed in B834-DE3 cells in SeMet Medium (Molecular Dimensions, MD12-500) following the manufacturer's instructions. For purification of His 6 and GST-tagged proteins, cells were resuspended in buffer containing 50 mM tris(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) pH 8.0, 200 mM NaCl, 1 mM tris (2-carboxyethyl)phosphine (TCEP), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1× protease inhibitor cocktail (Sigma) and lysed by sonication. Cells expressing StrepII-Avi-IKZF1Δ were lysed in the presence of 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 1 mM TCEP, 1 mM PMSF and 1× protease inhibitor cocktail (Sigma). Following ultracentrifugation, the soluble fraction was passed over the appropriate affinity resin Strep-Tactin Sepharose (IBA), Ni Sepharose 6 Fast Flow affinity resin (GE Healthcare), or Glutathione Sepharose 4B (GE Healthcare) and eluted with wash buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM TCEP) supplemented with 2.5 mM d-Desthiobiotin (IBA), 100 mM imidazole (Fischer Chemical), or 10 mM glutathione (Fischer BioReagents), respectively. SeMet-BRD4 BD1 affinity tag was TEV cleaved overnight. The affinity-purified protein was either further purified (CRBN-DDB1Δ B, IKZF1Δ , Spy-BRD4 BD1 ) via ion-exchange chromatography (Poros 50HQ) and subjected to size-exclusion chromatography or concentrated and directly subjected to size-exclusion chromatography in 50 mM HEPES pH 7.4, 200 mM NaCl and 1 mM TCEP. Biotinylation of IKZF1∆ and BRD4 BD1 , BRD4 BD2 variants was performed as previously described 43 .
The protein-containing fractions were concentrated using ultrafiltration (Millipore) and flash frozen in liquid nitrogen (DDB1∆ B-CRBN constructs at 40-120 μ M, biotinylated His 6 -Avi-BRD4 mutants and WT, and not biotinylated WT at ~25-100 μ M, SeMetBRD4 BD1 at 1 mM, biotinylated StrepII-Avi-IKZF1 at ~20 μ M concentration) and stored at − 80 °C or directly covalently labeled with BODIPY-FL-SpyCatcher S50C (His 6 -3C-Spy-CRBN-His 6 -DDB1Δ B, Spy-BRD4 BD1 ) as described below.
SpyCatcher S50C mutant. Spycatcher 42 containing a S50C mutation was obtained as a synthetic dsDNA fragment from IDT (Integrated DNA technologies) and subcloned as GST-TEV fusion protein in a pET-Duet derived vector. Spycatcher S50C was expressed in BL21-DE3, and cells were lysed in the presence of 50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM TCEP and 1 mM PMSF. Following ultracentrifugation, the soluble fraction was passed over Glutathione Sepharose 4B (GE Healthcare) and eluted with wash buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM TCEP) supplemented with 10 mM glutathione (Fischer BioReagents). The affinity-purified protein was subjected to size-exclusion chromatography, concentrated and flash frozen in liquid nitrogen.
Labeling of Spycatcher with BODIPY-FL-maleimide.
Purified Spycatcher S50C protein was incubated with DTT (8 mM) at 4 °C for 1 h. DTT was removed using a ENRich SEC650 10/300 (Bio-Rad) size-exclusion column in a buffer containing 50 mM Tris pH 7.5 and 150 mM NaCl, 0.1 mM TCEP. BODIPY-FL-maleimide (Thermo Fisher) was dissolved in 100% DMSO and mixed with Spycatcher S50C to achieve 2.5 molar excess of BODIPY-FL-maleimide. SpyCatcher S50C labeling was carried out at room temperature (RT, 20-24 ºC) for 3 h and stored overnight at 4 °C. Labeled Spycatcher S50C was purified on a ENRich SEC650 10/300 (Bio-Rad) sizeexclusion column in 50 mM Tris pH 7.5, 150 mM NaCl, 0.25 mM TCEP and 10% (v/v) glycerol, concentrated by ultrafiltration (Millipore), flash frozen (~40 μ M) in liquid nitrogen and stored at − 80 °C.
BODIPY-FL-Spycatcher labeling of CRBN-DDB1∆B and BRD4 BD1 .
Purified His 6 -DDB1∆ B-His 6 -3C-Spy-CRBN or His 6 -Spy-BRD4 BD1 was incubated overnight at 4 °C with BODIPY-FL labeled SpyCatcher S50C protein at stoichiometric ratio. Protein was concentrated and loaded on the ENrich SEC 650 10/300 (Bio-Rad) size-exclusion column and the labeling monitored with absorption at 280 and 490 nm. The protein peak corresponding to the labeled protein was pooled, concentrated by ultrafiltration (Millipore), flash frozen (~9.6 μ M for His 6 -DDB1∆ B-His 6 -3C-Spy-CRBN BODIPY SpyCatcher or ~22 μ M for His 6 -Spy-BRD4 BD1 ) in liquid nitrogen and stored at − 80 °C.
Crystallization and data collection. We have resorted to a previously developed DDB1 construct lacking WD40 propeller B (BPB, residues 396-705) domain (referred to as DDB1∆ B) successful in crystallization of a DDB1∆ B-CRBNlenalidomide-CK1α complex 17 . For crystallization of His 6 -DDB1∆ B-His 6 -CRBN-dBET6/23/70-his 6 -BRD4 BD1 and His 6 -DDB1∆ B-His 6 -CRBN-dBET55-His 6-Avi-BRD4 BD1(D145A) complexes, 145 μ M of dBET was mixed with 70 μ M BRD4 BD1 or BRD4 BD1 D145A and 80 μ M His 6 -DDB1∆ B-His 6 -CRBN and incubated for 15 min either on ice or at RT. Crystallization plates were set up in 3 sub-well plates (Intelli, Art Robbins) by vapor diffusion using NT8 (Formulatrix) at 20 °C, and images were acquired using RockImager 1000 (Formulatrix). Crystals appeared in wells B9-F9 and H9 of Morpheus HT Screen (Molecular Dimensions) within few hours and were fully grown after 3 d. Single uniform crystals (length, 80-100 μ m) were present in condition C9 (10% (w/v) PEG20k, 20% (w/v) PEG550 MME, 0.1 M BICINE pH 8.5) in 2:1 or 1:1 protein to precipitant ratio in 150 or 225 nL drops. Further optimization of condition in Morpheus HT Screen C9 by SilverBullet (Hampton Research) additive screening in 1:10 additive to reservoir ratio resulted in optimal crystals for dBET6, dBET23, dBET55 and dBET70 in Silver Bullet wells D7, B5, G4 and F2 respectively, in 2:1 protein to precipitant ratio of 225 or 400 nL drops. Crystals were cryo-protected in reservoir solution supplemented with 25-30% PEG 400 containing 150-300 μ M respective dBET and flash-cooled in liquid nitrogen. We have noticed that crystals harvested after 2-3 d resulted in optimal diffraction. Diffraction data were collected at the APS Chicago (beamline 24-ID-C) with a Pilatus 6M-F detector at a temperature of 100 K, or for the dBET6 co-crystal structure at beamline 24-ID-E with an Eiger 16 M detector at a temperature of 100 K. Data were indexed and integrated using XDS 44 and scaled using AIMLESS supported by other programs of the CCP4 suite 45 or RAPD pipeline (APS Chicago). Data processing statistics, refinement statistics and model quality parameters are provided in Supplementary Table 1. dBET57 containing crystals were obtained by mixing His 6 -DDB1∆ B-His 6 -CRBN at 75 µ M, with dBET57 at 140 µ M and SeMet BRD4 BD1 at 140 µ M in condition B5 of the Hampton Index HT screen (1.26 M NaH 2 PO 4 , 0.14 M K 2 HPO 4 ). Single crystals were harvested, stabilized by addition of 25% ethylene glycol containing dBET57 at 50 µ M. Diffraction data were collected at the APS Chicago (beamline 24-ID-C) with a Pilatus 6M-F detector at a temperature of 100 K, at a wavelength of 0.9724 Å. Data were indexed and integrated using RAPD pipeline (APS Chicago) and scaled using AIMLESS supported by other programs of the CCP4 suite 45 . Data processing statistics, refinement statistics and model quality parameters are provided in Supplementary Table 1 .
Structure determination and model building.
The DDB1∆ B-CRBN-dBET6/23/70-BRD4 BD1 and DDB1∆ B-CRBN-dBET55-BRD4 BD1/D145A quaternary complexes crystallized in space group P6 5 22 with a single complex in the unit cell. PHASER 46 was used to determine the structures by molecular replacement using a crystallographic model of DDB1∆ B-CRBN based on a crystal structure (PDB: 5FQD). The initial model was iteratively improved with COOT and refined using PHENIX.REFINE 47 and autoBUSTER 48 with ligand restraints generated by Grade server (Global Phasing) or phenix.elbow 49 . Protein geometry analysis revealed 0.46%, 0.54%, 1.01%, 0.72%, 0.77% Ramachandran outliers, with 95.36%, 94.87%, 92.96%, 93.67%, 93.66% residues in favored regions and 4.17%, 4.58%, 6.04%, 5.60%, 5.56% residues in allowed regions for the complexes with dBET6, 23, 55, 57 and 70, respectively.
The DDB1∆ B-CRBN-dBET57-SeMetBRD4 BD1 complex crystallized in space group I422 with a single complex in the unit cell. PHASER 46 was used for molecular replacement using models of hsDDB1∆ B-hsCRBN-HBD derived from PDB ID 5FQD, hsCRBN-NTD derived from 5FQD, and BRD4 BD1 (PDB: 3MXF). The model was rigid body refined using PHENIX.REFINE 47 , and the hsCRBN-CTD was subsequently placed using Coot jiggle fit (part of Coot EM scripts from A. Brown and P. Emsley). The final model was rigid body refined using PHENIX.REFINE and autoBUSTER 48 . Anomalous maps were calculated with PHENIX.MAPS 47 .
Figures were generated with PyMOL (The PyMOL Molecular Graphics System, Version 1.8.6.0 Schrödinger, LLC), and model quality was assessed with MOLPROBITY 50 . Interaction surfaces were determined with PISA 31 . The IKZF1 homology model was taken from ref. 17 .
Time-resolved fluorescence resonance energy transfer (TR-FRET).
Compounds in dimerization assays were dispensed in a 384-well microplate (Corning, 4514) using D300e Digital Dispenser (HP) normalized to 2% DMSO into 200 nM biotinylated His 6 -avi-bromodomain (WT or mutant, see figure legends) or 80 nM biotinylated StrepII-avi-IKZF1∆ (See figure legends), 100 nM His 6 -DDB1∆ B-His 6 -CRBN BODIPY-Spycatcher and 2 nM terbium-coupled streptavidin (Invitrogen) in a buffer containing 50 mM Tris pH 7.5, 200 mM NaCl, 0.1% Pluronic F-68 solution (Sigma) and 2% DMSO (4% DMSO final). Compounds in CRBN mutants dimerization assay were dispensed as described above into 200 nM His 6 -DDB1-His 6 -CRBN mutants or 200 nM His 6 -DDB1∆ B-His 6 -CRBN WT , 100 nM BRD4 BD1 -BODIPY-SpyCatcher and 2 nM terbium-anti-HIS Ab (Invitrogen) in a buffer containing 50 mM Tris pH 7.5, 200 mM NaCl, 0.1% Pluronic F-68 solution (Sigma) and 2% DMSO (4% DMSO final). Before TR-FRET measurements were conducted, the reactions were incubated for 15 min at RT. After excitation of terbium fluorescence at 337 nm, emission at 490 nm (terbium) and 520 nm (BODIPY) were recorded with a 70 μ s delay over 600 μ s to reduce background fluorescence, and the reaction was followed over 30 200 s cycles of each data point using a PHERAstar FS microplate reader (BMG Labtech). The TR-FRET signal of each data point was extracted by calculating the 520/490 nm ratio. The heterobifunctional nature of small-molecule degraders results in a three-body binding equilibrium complicated by potential 1 nature research | life sciences reporting summary Corresponding author(s): Eric S. Fischer
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Experimental design 1. Sample size
Describe how sample size was determined. All statistical approaches are described and discussed in the methods section and figure legends. 3 biological replicates for proteomics experiments were chosen to ensure sufficient statistical power and false discovery rates have been controlled when appropriate. For cellular and biochemical experiments at least three independent biological replicates were conducted.
Data exclusions
Describe any data exclusions. N/A
Replication
Describe whether the experimental findings were reliably reproduced.
All experiments were found reproducible. Number of replicates are indicated.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The results are quantitative (TR-FRET, FP assays, X-ray crystallography, mass spectrometry) or semi-quantitative (Western Blot) and would not significantly benefit form sample randomization.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Our study did not involve clinical trials, patient samples, or animal studies; therefore, blinding was not required.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
